Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65...
Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions
About this item
Full title
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
AbstractBackgroundIn June 2021, the Advisory Committee on Immunization Practices (ACIP) recommended use of either 20-valent pneumococcal conjugate vaccine (PCV20) alone or 15-valent pneumococcal conjugate vaccine (PCV15) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all PCV-unvaccinated adults aged ≥65 years (age-based)...
Alternative Titles
Full title
Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_3146570960
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3146570960
Other Identifiers
ISSN
0264-410X,1873-2518
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2024.126567
